Fortis Healthcare has announced an ambitious expansion strategy that will significantly enhance its healthcare infrastructure across India. The company's comprehensive growth plan demonstrates its commitment to strengthening its position in the competitive healthcare sector.

Expansion Strategy and Capacity Enhancement

The healthcare provider has outlined plans for aggressive expansion, targeting the addition of over 3,200 beds by 2030. This substantial capacity increase represents a major milestone in the company's growth trajectory and reflects its confidence in the expanding healthcare market in India.

Strategic Acquisitions and Geographic Expansion

As part of its expansion roadmap, Fortis Healthcare is making strategic acquisitions in key markets including Bangalore and Punjab. These acquisitions are expected to strengthen the company's presence in these important healthcare markets and provide enhanced access to quality healthcare services for patients in these regions.

Corporate Developments and Financial Milestones

The company has successfully completed the closure of the IHH Open Offer, marking an important corporate milestone. This development provides clarity on the company's ownership structure and strategic direction moving forward.

Operational Performance and Medical Tourism Growth

Fortis Healthcare is experiencing positive momentum across several key operational metrics. The company is witnessing growth in medical tourism, indicating increased confidence from international patients seeking quality healthcare services. Additionally, the organization is reporting improvements in Average Revenue Per Occupied Bed (ARPOB) and occupancy rates, reflecting enhanced operational efficiency and patient demand.

Diagnostic Services Focus

The company is placing increased emphasis on its diagnostic B2C segment, recognizing the growing demand for direct-to-consumer diagnostic services. This strategic focus aligns with evolving patient preferences and the increasing importance of preventive healthcare in the Indian market.

Fortis Healthcare Limited has released its comprehensive investor presentation materials for the upcoming US investor meetings scheduled from January 12-15, 2026. The healthcare major submitted the presentation titled "Non-Deal Roadshow / JP Morgan 2026 Healthcare Conference" to stock exchanges on January 8, 2026, following its earlier announcement of the investor engagement schedule.

Presentation Submission and Compliance

The company filed the investor presentation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, continuing its commitment to regulatory transparency. Company Secretary & Compliance Officer Satyendra Chauhan digitally signed the submission, confirming the presentation will be used for interactions with investors and analysts during the scheduled events.

Business Performance Highlights

The presentation reveals strong consolidated business performance with significant growth momentum. The hospital and diagnostics business achieved a revenue compound annual growth rate of 10.90% from FY20-25, while operational EBITDA demonstrated robust expansion at 20.80% CAGR over the same period.

Network Expansion and Infrastructure

Fortis Healthcare operates an extensive network of 34 healthcare facilities with approximately 5,900 operational beds, including around 1,200 O&M beds. The network spans multiple states with significant presence in key metropolitan areas including the National Capital Region, Mumbai, Bengaluru, and Punjab.

The company's diagnostic division, Agilus Diagnostics, maintains over 400 laboratories serving 8.6 million patients in H1FY26, conducting 20.7 million tests through 4,300+ customer touch points across 25 states and 2 Union Territories.

Ambitious Growth Strategy

The presentation outlines aggressive expansion plans with planned capacity addition of 3,200+ beds from FY25 to FY30, representing a compound annual growth rate of 10.70%. Recent corporate developments include multiple acquisitions and operational management agreements, significantly expanding the company's footprint.

Clinical Excellence and Technology Leadership

The company demonstrated strong clinical performance in H1FY26, conducting over 37,200 cardiac procedures, 18,400 joint replacements and orthopedic procedures, and 4,900+ robotic surgeries. The network features state-of-the-art medical equipment including 11 Da Vinci robots, 17 orthopedic robots, and advanced imaging technologies.

Meeting Schedule and Investor Engagement

The structured investor engagement includes a non-deal roadshow organized with J.P. Morgan covering New York and Boston on January 12-13, 2026, followed by participation in the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 15, 2026. The company confirmed strict adherence to regulatory requirements, ensuring no Unpublished Price Sensitive Information will be shared during these meetings.